Vaginal Fluid Derived Biomarkers in the Early Detection and Evolution of Gynaecological Cancers

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorUniversity Hospital Southampton NHS Foundation Trust

About this trial

This study will investigate vaginal secretions in those patients with cancer versus those who are cancer free and compare changes in specific markers that change when a cancer first develops.

Patients who are being investigated for any gynaecological cancer, undergoing surgery to reduce their risk of gynaecological cancer and those with confirmed gynaecological cancer undergoing anti-cancer treatment will be approached to take part in this study.

Participants will be asked to provide an extra blood test, urine sample and high vaginal swab in addition to surplus primary tissue and ascitic fluid that is left over from routine surgical procedures. Specific markers will be compared in patients who have evidence of gynaecological cancer versus those that do not. Changes in these markers during anti-cancer treatment will also be compared to see how these change over time. This could improve the detection and monitoring of gynaecological cancers in those people at highest risk of developing it by using non-invasive multi-cancer early detection tests developed at the University of Southampton.

Eligibility criteria

Qualifiers

Suspected cohort: Individuals undergoing investigations for suspected gynaecological cancer. This includes patients undergoing surgery to reduce their risk of the development of gynaecological cancers in the future

Confirmed treatment cohort: Individuals with a confirmed gynaecological cancer diagnosis undergoing anti-cancer treatment including surgical resection, chemotherapy or radiotherapy as part of their routine clinical care

Confirmed palliative cohort: Individuals with a confirmed gynaecological cancer diagnosis undergoing palliative procedures including ascitic drainage as part of their routine clinical care

Disqualifiers

Patients under 18 years old

Individuals who lack capacity to consent to trial participation

Pregnant or breastfeeding patients

Patients with active vaginal infection

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

250 Participants
are grouped into 3 trial groups

Sponsors and collaborators

University Hospital Southampton NHS Foundation Trust

Lead sponsor

Experimental Cancer Medicine Centres

Collaborator

The Eve Appeal

Collaborator

Southampton Clinical Trials Unit

Collaborator

Daye BioTech

Collaborator

University of Oxford

Collaborator